SNY - Bernie Sanders Targets High Prices of Ozempic and Wegovy In US | Benzinga
Senator Bernie Sanders expressed confidence that Novo Nordisk A/S (NYSE:NVO) can be persuaded to reduce the U.S. prices of its popular weight-loss drugs, Ozempic and Wegovy, by publicly highlighting the disparity between domestic and international pricing.
Sanders, who chairs the Senate Committee on Health, Education, Labor, and Pensions (HELP), plans to question Novo Nordisk CEO Lars Jorgensen during a September hearing focused on these drugs’ U.S. prices.
The Vermont senator’s strategy proved effective last year when he pressured Novo Nordisk, Eli Lilly And Co (NYSE:LLY), and Sanofi SA (NASDAQ:SNY) to lower insulin prices.
“I think we got a real shot, and I was pleased ...